NCT00967356View on ClinicalTrials.gov

AZD5985 Single Ascending Dose Study

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Study Completion Date

November 30, 2009

Conditions

Healthy

Interventions

DRUG

AZD5985

Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits

DRUG

Placebo

Oral suspension

Trial Locations (1)

Unknown

Research Site, Gothenburg